Fortrea Holdings (FTRE) Gross Profit (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Gross Profit came in at $139.2 million in Q2 2026, up 4.27% YoY from $133.5 million in Q2 2025, and up 12.62% on a QoQ basis from $123.6 million in Q1 2026.
Fortrea Holdings (FTRE) Gross Profit (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Gross Profit data on file, last reported at $139.2 million in Q2 2026.
- Quarterly Gross Profit rose 4.27% year-over-year to $139.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $516.6 million (down 4.19% YoY) and the FY2025 annual result came in at $503.8 million, down 5.69% from the prior year.
- Gross Profit climbed to $139.2 million in Q2 2026, from $123.6 million in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $237.6 million in Q4 2022 to a low of $107.9 million in Q1 2024.
- A 5-year average of $145.6 million and a median of $139.2 million in 2026 frame the typical range for Gross Profit.
- Annual changes were most pronounced in 2023 — Gross Profit tumbled 44.53% — and 2025, when it advanced 7.97%.
- Tracing FTRE's Gross Profit over 5 years: stood at $237.6 million in 2022, then plunged by 44.53% to $131.8 million in 2023, then climbed by 6.9% to $140.9 million in 2024, then decreased by 6.96% to $131.1 million in 2025, then rose by 6.18% to $139.2 million in 2026.
- The last three Gross Profit figures came in at $139.2 million (Q2 2026), $123.6 million (Q1 2026), and $131.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Fortrea Holdings | 1.66 Bn | 1.49 Bn | 139.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 139.20 Mn |
| Jun 30, 2026 | 139.20 Mn |
| Mar 31, 2026 | 123.60 Mn |
| Mar 31, 2026 | 123.60 Mn |
| Dec 31, 2025 | 131.10 Mn |
| Dec 31, 2025 | 131.10 Mn |
| Sep 30, 2025 | 122.70 Mn |
| Sep 30, 2025 | 122.70 Mn |
| Jun 30, 2025 | 133.50 Mn |
| Jun 30, 2025 | 133.50 Mn |
| Mar 31, 2025 | 116.50 Mn |
| Mar 31, 2025 | 116.50 Mn |
| Dec 31, 2024 | 140.90 Mn |
| Dec 31, 2024 | 140.90 Mn |
| Sep 30, 2024 | 148.30 Mn |
| Sep 30, 2024 | 148.30 Mn |
| Jun 30, 2024 | 137.10 Mn |
| Jun 30, 2024 | 137.10 Mn |
| Mar 31, 2024 | 107.90 Mn |
| Mar 31, 2024 | 107.90 Mn |